Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer

Authors: Venkatakrishna Rao Jala, Brandie N Radde, Bodduluri Haribabu, Carolyn M Klinge

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

G-protein-coupled estrogen receptor (GPER/GPR30) was reported to bind 17β-estradiol (E2), tamoxifen, and ICI 182,780 (fulvestrant) and promotes activation of epidermal growth factor receptor (EGFR)-mediated signaling in breast, endometrial and thyroid cancer cells. Although lung adenocarcinomas express estrogen receptors α and β (ERα and ERβ), the expression of GPER in lung cancer has not been investigated. The purpose of this study was to examine the expression of GPER in lung cancer.

Methods

The expression patterns of GPER in various lung cancer lines and lung tumors were investigated using standard quantitative real time PCR (at mRNA levels), Western blot and immunohistochemistry (IHC) methods (at protein levels). The expression of GPER was scored and the pairwise comparisons (cancer vs adjacent tissues as well as cancer vs normal lung tissues) were performed.

Results

Analysis by real-time PCR and Western blotting revealed a significantly higher expression of GPER at both mRNA and protein levels in human non small cell lung cancer cell (NSCLC) lines relative to immortalized normal lung bronchial epithelial cells (HBECs). The virally immortalized human small airway epithelial cell line HPL1D showed higher expression than HBECs and similar expression to NSCLC cells. Immunohistochemical analysis of tissue sections of murine lung adenomas as well as human lung adenocarcinomas, squamous cell carcinomas and non-small cell lung carcinomas showed consistently higher expression of GPER in the tumor relative to the surrounding non-tumor tissue.

Conclusion

The results from this study demonstrate increased GPER expression in lung cancer cells and tumors compared to normal lung. Further evaluation of the function and regulation of GPER will be necessary to determine if GPER is a marker of lung cancer progression.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011. CA Cancer J Clin. 2011, 61: 212-236.CrossRefPubMed
2.
Ramchandran K, Patel JD: Sex Differences in Susceptibility to Carcinogens. Semin Oncol. 2009, 36: 516-523.CrossRefPubMed
3.
Kiyohara C, Ohno Y: Sex differences in lung cancer susceptibility: a review. Gender Medicine. 2010, 7: 381-401.CrossRefPubMed
4.
Bouchardy C, Benhamou S, Schaffar R, Verkooijen HM, Fioretta G, Schubert H, Vinh-Hung V, Soria J-C, Vlastos G, Rapiti E: Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer. 2011, 117: 1288-1295.CrossRefPubMed
5.
Dubey S, Siegfried JM, Traynor AM: Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol. 2006, 7: 416-424.CrossRefPubMed
6.
Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005, 70: 372-381.CrossRefPubMed
7.
Drummond AE, Britt KL, Dyson M, Jones ME, Kerr JB, O'Donnell L, Simpson ER, Findlay JK: Ovarian steroid receptors and their role in ovarian function. Mol Cell Endocrinol. 2002, 191: 27-33.CrossRefPubMed
8.
O'Donnell L, Robertson KM, Jones ME, Simpson ER: Estrogen and spermatogenesis. Endocr Rev. 2001, 22: 289-318.CrossRefPubMed
9.
10.
11.
Townson SM, O'Connell P: Identification of estrogen receptor alpha variants in breast tumors: implications for predicting response to hormonal therapies. J Surg Oncol. 2006, 94: 271-273.CrossRefPubMed
12.
Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D: Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000, 2000: 75-93.CrossRef
13.
Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA: Mechanisms of estrogen action. Physiol Rev. 2001, 81: 1535-1565.PubMed
14.
Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson J-Å, Dahlman-Wright K: Genome-Wide Mapping of Estrogen Receptor-β–Binding Regions Reveals Extensive Cross-Talk with Transcription Factor Activator Protein-1. Cancer Res. 2010, 70: 5174-5183.CrossRefPubMed
15.
Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V: Endocrine therapy of breast cancer. Curr Med Chem. 2011, 18: 513-522.CrossRefPubMed
16.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997, 138: 863-870.PubMed
17.
Mollerup S, Jorgensen K, Berge G, Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer. 2002, 37: 153-159.CrossRefPubMed
18.
Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, Finkelstein S, Siegfried JM: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002, 62: 2141-2150.PubMed
19.
Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005, 65: 1459-1470.CrossRefPubMed
20.
Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM: Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer. 2006, 13: 113-134.CrossRefPubMedPubMedCentral
21.
Ivanova MM, Mazhawidza W, Dougherty SM, Klinge CM: Sex Differences in Estrogen Receptor Subcellular Location and Activity in Lung Adenocarcinoma Cells. Am J Respir Cell Mol Biol. 2010, 42: 320-330.CrossRefPubMed
22.
Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM: Activity and intracellular location of estrogen receptors [alpha] and [beta] in human bronchial epithelial cells. Mol Cell Endocrinol. 2009, 205: 12-21.CrossRef
23.
Watson CS, Jeng Y-J, Kochukov MY: Nongenomic Signaling Pathways of Estrogen Toxicity. Toxicol Sci. 2010, 115: 1-11.CrossRefPubMed
24.
Jeng Y-J, Kochukov M, Watson C: Membrane estrogen receptor-alpha-mediated nongenomic actions of phytoestrogens in GH3/B6/F10 pituitary tumor cells. J Mol Signal. 2009, 4: 2-CrossRefPubMedPubMedCentral
25.
Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW: Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem. 2001, 276: 27071-27076.CrossRefPubMed
26.
Kelly MJ, Levin ER: Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab. 2001, 12: 152-156.CrossRefPubMed
27.
Levin ER: Minireview: Extranuclear Steroid Receptors: Roles in Modulation of Cell Functions. Mol Endocrinol. 2011, 25: 377-384.CrossRefPubMed
28.
Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003, 278: 2701-2712.CrossRefPubMed
29.
Zhang G, Liu X, Farkas AM, Parwani AV, Lathrop KL, Lenzner D, Land SR, Srinivas H: Estrogen Receptor Beta Functions through Non-genomic Mechanisms in Lung Cancer Cells. Mol Endocrinol. 2009, 23: 137-145.CrossRefPubMed
30.
Majidi M, Al-Wadei HA, Takahashi T, Schuller HM: Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res. 2007, 67: 6863-6871.CrossRefPubMed
31.
Levin ER: Cell localization, physiology, and nongenomic actions of estrogen receptors. J Appl Physiol. 2001, 91: 1860-1867.PubMed
32.
Audy MC, Vacher P, Duly B: 17 beta-estradiol stimulates a rapid Ca2+ influx in LNCaP human prostate cancer cells. Eur J Endocrinol. 1996, 135: 367-373.CrossRefPubMed
33.
Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL: A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 1992, 131: 1305-1312.PubMed
34.
Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A. 1994, 91: 8517-8521.CrossRefPubMedPubMedCentral
35.
Le Mellay V, Grosse B, Lieberherr M: Phospholipase C beta and membrane action of calcitriol and estradiol. J Biol Chem. 1997, 272: 11902-11907.CrossRefPubMed
36.
Song RX, Santen RJ: Membrane initiated estrogen signaling in breast cancer. Biol Reprod. 2006, 75: 9-16.CrossRefPubMed
37.
Manavathi B, Kumar R: Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol. 2006, 207: 594-604.CrossRefPubMed
38.
Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 231-238.CrossRefPubMed
39.
Filardo EJ, Quinn JA, Bland KI, Frackelton AR: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000, 14: 1649-1660.CrossRefPubMed
40.
Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006, 12: 6359-6366.CrossRefPubMed
41.
Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ: Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 2008, 70: 165-190.CrossRefPubMed
42.
43.
44.
Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, et al: The G Protein–Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor–Positive Breast Cancer Cells. Cancer Res. 2010, 70: 1184-1194.CrossRefPubMedPubMedCentral
45.
Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C: A critical review of fundamental controversies in the field of GPR30 research. Steroids. 2010, 75: 603-610.CrossRefPubMed
46.
Barton M: Position paper: The membrane estrogen receptor GPER/GPR30: Clues and questions. Steroids. 2012, 77: 935-942.CrossRefPubMed
47.
Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997, 45: 607-617.CrossRefPubMed
48.
Feng Y, Gregor P: Cloning of a Novel Member of the G Protein-Coupled Receptor Family Related to Peptide Receptors. Biochem Biophys Res Commun. 1997, 231: 651-654.CrossRefPubMed
49.
Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, et al: Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004, 64: 9027-9034.CrossRefPubMed
50.
Masuda A, Kondo M, Saito T, Yatabe Y, Kobayashi T, Okamoto M, Suyama M, Takahashi T, Takahashi T: Establishment of Human Peripheral Lung Epithelial Cell Lines (HPL1) Retaining Differentiated Characteristics and Responsiveness to Epidermal Growth Factor, Hepatocyte Growth Factor, and Transforming Growth Factor β1. Cancer Res. 1997, 57: 4898-4904.PubMed
51.
Al-Wadei HAN, Al-Wadei MH, Masi T, Schuller HM: Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer. 2010, 69: 33-39.CrossRefPubMed
52.
Schuller HM, Al-Wadei HAN, Majidi M: Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis. 2008, 29: 1979-1985.CrossRefPubMedPubMedCentral
53.
Maiti K, Paul JW, Read M, Chan EC, Riley SC, Nahar P, Smith R: G-1-Activated Membrane Estrogen Receptors Mediate Increased Contractility of the Human Myometrium. Endocrinology. 2011, 152: 2448-2455.CrossRefPubMed
54.
Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF: The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc. 2006, 2006: 145-161.
55.
Rios CD, Jordan BA, Gomes I, Devi LA: G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacology & Therapeutics. 2001, 92: 71-87.CrossRef
56.
Sandén C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Mårtensson UEA, Olde B, Leeb-Lundberg LMF: G Protein-Coupled Estrogen Receptor 1/G Protein-Coupled Receptor 30 Localizes in the Plasma Membrane and Traffics Intracellularly on Cytokeratin Intermediate Filaments. Mol Pharmacol. 2011, 79: 400-410.CrossRefPubMed
57.
Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O: GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. The Journal of steroid biochemistry and molecular biology. 2010, 118: 7-12.CrossRefPubMed
58.
Prossnitz ER, Barton M: The G-protein-coupled estrogen receptor GPER in health and disease. 2011, Endocrinology: Nature reviews
59.
Tu G, Hu D, Yang G, Yu T: The correlation between GPR30 and clinicopathologic variables in breast carcinomas. Technol Cancer Res Treat. 2009, 8: 231-234.CrossRefPubMed
60.
Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER: GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007, 196 (386): e381-e389. discussion 386 e389-311
61.
Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006, 20: 631-646.CrossRefPubMed
62.
Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 2009, 114: 465-471.CrossRefPubMedPubMedCentral
63.
Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Ando S, Maggiolini M: 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol. 2006, 70: 1414-1423.CrossRefPubMed
64.
Luo HJ, Luo P, Yang GL, Peng QL, Liu MR, Tu G: G-protein Coupled Estrogen Receptor 1 Expression in Primary Breast Cancers and Its Correlation with Clinicopathological Variables. J Breast Cancer. 2011, 14: 185-190.CrossRefPubMedPubMedCentral
65.
Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M: GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat. 2010, 123: 51-58.CrossRefPubMed
66.
Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Oyan AM, Stefansson IM, Kalland KH, et al: Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. Br J Cancer. 2012, 106: 1682-1688.CrossRefPubMedPubMedCentral
67.
Gao F, Ma X, Ostmann AB, Das SK: GPR30 Activation Opposes Estrogen-Dependent Uterine Growth via Inhibition of Stromal ERK1/2 and Estrogen Receptor Alpha (ERα) Phosphorylation Signals. Endocrinology. 2011, 152: 1434-1447.CrossRefPubMedPubMedCentral
68.
Fasco MJ, Hurteau GJ, Spivack SD: Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol. 2002, 188: 125-140.CrossRefPubMed
69.
Stabile LP, Siegfried JM: Sex and gender differences in lung cancer. J Gend Specif Med. 2003, 6: 37-48.PubMed
70.
71.
Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH: G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology. 2008, 149: 4846-4856.CrossRefPubMed
72.
Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY: Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 2010, 24: 709-721.CrossRefPubMedPubMedCentral
73.
Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, et al: GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod. 2009, 80: 34-41.CrossRefPubMed
74.
Ahola TM, Alkio N, Manninen T, Ylikomi T: Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology. 2002, 143: 4620-4626.CrossRefPubMed
75.
Ahola TM, Manninen T, Alkio N, Ylikomi T: G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology. 2002, 143: 3376-3384.CrossRefPubMed
76.
Ahola TM, Purmonen S, Pennanen P, Zhuang YH, Tuohimaa P, Ylikomi T: Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur J Biochem. 2002, 269: 2485-2490.CrossRefPubMed
77.
Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M: G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells. Cancer Res. 2007, 67: 1859-1866.CrossRefPubMed
78.
Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an Estrogen Membrane Receptor Coupled to a G Protein in Human Breast Cancer Cells. Endocrinology. 2005, 146: 624-632.CrossRefPubMed
79.
Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ: Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci. 2011, 16: 116-130.CrossRef
80.
Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G: American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011
81.
Girgert R, Emons G, Grundker C: Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat. 2012, 134: 199-205.CrossRefPubMedPubMedCentral
Metadata
Title
Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer
Authors
Venkatakrishna Rao Jala
Brandie N Radde
Bodduluri Haribabu
Carolyn M Klinge
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-624

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

The effect of metformin and thiazolidinedione use on lung cancer in diabetics

Research article

Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer

Research article

The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature

Research article

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

Research article

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

Research article

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits